Cellectis (CLLS) Consolidated Net Income (2015 - 2026)
Cellectis' (CLLS) quarterly Consolidated Net Income came in at -$8.9 million in Q1 2026, down 475.31% year-on-year from $2.4 million in Q1 2025, and up 91.67% quarter-over-quarter from -$106.6 million in Q4 2025.
Cellectis (CLLS) Consolidated Net Income (2015 - 2026) Analysis & Trends
Cellectis' Consolidated Net Income history runs 12 years deep, the most recent figure standing at -$8.9 million for Q1 2026.
- On a quarterly basis, Consolidated Net Income fell 475.31% year-over-year to -$8.9 million in Q1 2026; TTM through Mar 2026 was -$77.4 million, a 145.36% decrease from a year earlier, with the FY2023 full-year figure at $8.4 million, up 154.69% from the prior year.
- Consolidated Net Income grew to -$8.9 million in Q1 2026 per CLLS's latest filing, from -$106.6 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $22.4 million in Q3 2025 and bottomed at -$106.6 million in Q4 2025.
- The 5-year median for Consolidated Net Income is -$2.9 million (2022), against an average of -$8.9 million.
- Across the five-year window, Consolidated Net Income jumped 3059.95% in 2023 and sank 475.31% in 2026, its largest moves.
- Year by year, Consolidated Net Income stood at -$2.9 million in 2022, then surged by 557.93% to $13.1 million in 2023, then tumbled by 418.45% to -$41.7 million in 2024, then slumped by 155.8% to -$106.6 million in 2025, then soared by 91.67% to -$8.9 million in 2026.
- Per Business Quant, the three latest CLLS Consolidated Net Income figures stand at -$8.9 million (Q1 2026), -$106.6 million (Q4 2025), and $22.4 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | -8.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.88 Mn |
| Dec 31, 2025 | -106.57 Mn |
| Sep 30, 2025 | 22.41 Mn |
| Jun 30, 2025 | 15.65 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | -41.66 Mn |
| Sep 30, 2024 | 7.76 Mn |
| Jun 30, 2023 | 13.08 Mn |
| Mar 31, 2023 | -4.69 Mn |
| Dec 31, 2022 | -2.86 Mn |
| Sep 30, 2022 | -5.72 Mn |
| Jun 30, 2022 | -442,000.00 |
| Mar 31, 2022 | -6.44 Mn |
| Dec 31, 2021 | -6.65 Mn |
| Sep 30, 2021 | -44.56 Mn |
| Jun 30, 2021 | -36.17 Mn |
| Mar 31, 2021 | -10.03 Mn |
| Dec 31, 2020 | -51.58 Mn |
| Sep 30, 2020 | -30.25 Mn |
| Jun 30, 2020 | -35.09 Mn |